Technology holding company Coastal Holdings, has purchased a
significant equity interest in another biotechnology business,
adding to its portfolio of acquisitions and investments in the
biotechnology and nanotechnology fields.
A unique approach to microdosing, providing drug data ahead of
schedule and with improved accuracy, could herald a new era in drug
development in which human ADME data is involved in candidate
selection or deselection.
UK biotechnology company CellFactors has entered administration
following its failure to raise additional funds to further develop
its product Skeletex, a biological matrix derived from human cells
that induces new vascularised bone...
Drug discovery company Ablynx is to enter into a partnership with
Proctor and Gamble Pharmaceuticals. The agreement will make use of
Ablynx's Nanobody platform to develop drug candidates against a
G-protein coupled receptor (GPCR)...
Drug development company Jerini has transferred its peptide
technologies business unit to a wholly owned subsidiary which will
continue to provide and develop peptide-based services and products
for biomedical research.
Moscow, Russia-based Quantum Pharmaceuticals is offering
pharmaceutical and biotechnology companies the opportunity to test
the latest version of its molecular docking software - Quantum 2.0
- at no cost, reports Phil Taylor.
BD Biosciences has acquired Atto Bioscience in a deal worth $25
million (€20m), allowing it to enter the emerging high content cell
analysis market and enhancing its presence in the pharmaceutical
and biotechnology sectors.
In the UK, a groundbreaking partnership between government and
industry has led to the creation of a National Biomanufacturing
Centre, designed to make it easier for fledgling biotechnology
companies to get access to contract manufacturing...
Boehringer Ingelheim has been granted a US patent on a way to
disguise real and placebo tablets in a clinical trial - without
having to resort to placing them in larger capsules which may be
difficult for patients to swallow.
Qiagen has sold off its embattled nucleic acid synthesis business
in a management buyout, but has retained a minority stake and all
activities relating to RNA interference (RNAi), a potent new drug
Charles River Laboratories has made a $1.5 billion (€1.2bn) bid to
acquire Inveresk Research in a deal that will create a contract
research powerhouse with nearly $1 billion in annual revenues,
writes Phil Taylor.
Companies developing new drugs for the global market must deal with
the rising costs of the R&D process - and outsourcing may well
be the best route, according to Dr Faiz Kermani, a specialist in
outsourcing and research development.
Despite a dip in the fortunes of the biotechnology industry,
bioinformatics firm BlueGnome has achieved profit in less than
three years since its formation. The firm's fortunes are in
contrast to similar start up firms within...
A clear legal basis has been established for the first time which
will enable research institutions to use molecular biology
techniques for which provate companies have dominant patent
positions without signing away the rights to...